Lupin to Focus on Biosimilars, Inhalation and Complex Generics to Improve Profitability, an Industrial Info Market Brief

---

Lupin Limited, India's third-largest drugmaker, said it will focus on execution of its complex generics pipeline, biosimilars and inhalation portfolio to improve profitability, as the company continues to face pricing pressure and regulatory challenges in the U.S. market.

"On the inhalation front, we filed our first DPI (dry-powder inhaler) in the U.S.," said the company in its annual report. "We are the only Indian company to have filed a DPI as well as MDI (metered-dose inhaler) in the U.S." By 2020, the company plans to bring its first biosimilar to the market and commercialize its first inhalation product in the U.S.

Industrial Info is tracking Lupin's manufacturing assets involving oral formulations, injectables and active pharmaceutical ingredients (API). Industrial Info's database tracks 832 pharmaceutical and biotech plants in India, with more than 3,500 functional management contacts. Click here for a list, and see map below for Lupin's facilities.